Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion type Assertion NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_head.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion evidence source_evidence_literature NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion SIO_000772 22021366 NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion wasDerivedFrom befree-20150227 NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.
- NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion wasGeneratedBy ECO_0000203 NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.